GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 1, 2024, serves as a notification to the market regarding the Company's total voting rights and capital structure. The data reflects the status as of October 31, 2024, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
Material Changes
The filing does not disclose material changes compared to a prior comparable period. It provides a static snapshot of the share capital structure as of the reporting date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Key Facts for Investors
- Issued Share Capital: As of October 31, 2024, GSK Plc had 4,314,270,856 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 169,171,155 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,145,099,701.
- Regulatory Use: Shareholders should use the total voting rights figure (4,145,099,701) as the denominator when determining if they must notify their interest or changes in interest under FCA rules.